Cargando…

Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases

Background KLS-1 is zinc (Zn) aspartate enriched with isotope (64)Zn to 99.2% mass fraction of total zinc. KLS-1 is intended as a novel therapeutic approach for patients with a variety of diseases including but not limited to different forms of cancer and neurodegenerative diseases. The purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez, Jesus A, Lopez, Javier J, Torres Badillo, Claudia C, Gill, Jaya, Kesari, Santosh, Novak, Peter, Temnikov, Max, Byshovets, Roman, Bychkov, Oleg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637427/ https://www.ncbi.nlm.nih.gov/pubmed/36381721 http://dx.doi.org/10.7759/cureus.29921

Ejemplares similares

Correction: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases
por: Perez, Jesus A, et al.
Publicado: (2022)

Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer
por: Juarez, Tiffany M, et al.
Publicado: (2021)

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
por: Liu, Dan, et al.
Publicado: (2022)

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts
por: Bang, Yung‐Jue, et al.
Publicado: (2019)

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
por: Smith, David C., et al.
Publicado: (2018)

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer
por: Chen, Justin A., et al.
Publicado: (2022)

A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy Subjects
por: Lee, Ko-Onn, et al.
Publicado: (2016)

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
por: Ramasamy, Karthik, et al.
Publicado: (2021)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
por: Bendell, Johanna C, et al.
Publicado: (2017)

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
por: Harding, James J., et al.
Publicado: (2021)

Comment on: “A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-aspartate Angiotensin I in Healthy Subjects”
por: Srinivas, Nuggehally R.
Publicado: (2016)

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
por: Shi, Yuankai, et al.
Publicado: (2022)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

The Application of the Gibson Assembly Method in the Production of Two pKLS3 Vector-Derived Infectious Clones of Foot-and-Mouth Disease Virus
por: Semkum, Ploypailin, et al.
Publicado: (2023)

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies
por: Ho, Jingshan, et al.
Publicado: (2022)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer
por: Myint, Zin W., et al.
Publicado: (2023)

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Protocol for Multi-modality MEdical imaging sTudy bAsed on KaiLuan Study (META-KLS): rationale, design and database building
por: Sun, Jing, et al.
Publicado: (2023)

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
por: Wang, Xuan, et al.
Publicado: (2023)

Author’s Reply to Srinivas: “A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy Subjects”
por: Sim, Meng-Kwoon, et al.
Publicado: (2016)

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
por: Li, Huiping, et al.
Publicado: (2020)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
por: Lickliter, Jason D., et al.
Publicado: (2021)

Neural network dose prediction for rectal spacer stratification in dose‐escalated prostate radiotherapy
por: Thomas, Christopher, et al.
Publicado: (2022)

Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer
por: Jo, Sunmi, et al.
Publicado: (2016)

Dose‐escalation strategies which use subgroup information
por: Cotterill, Amy, et al.
Publicado: (2018)

Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma
por: Tensaouti, Fatima, et al.
Publicado: (2019)

Safety and tolerability of escalating cannabinoid doses in healthy cats
por: Kulpa, Justyna E, et al.
Publicado: (2021)

Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
por: Rozental, Aaron J., et al.
Publicado: (2022)

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
por: Dasari, Arvind, et al.
Publicado: (2023)

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vvh0v0bve0a6l7p2bpo17usaj6